Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.61 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.61 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.61 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28143495 | 0.79 | SIRT1 (0.67) | SIRT1SIRT3SIRT5SIRT2ADORA2B | |
| SCHEMBL5400398 | 0.79 | SIRT1 (0.67) | SIRT1SIRT3SIRT5SIRT2ADORA2B | |
| SCHEMBL7201941 | 0.77 | SIRT1 (0.62) | SIRT1SIRT3SIRT5SIRT2ADORA2B | |
| SCHEMBL11033222 | 0.76 | ALDH1A1 (0.60) | SIRT1SIRT3SIRT5SIRT2ADORA2B | |
| SCHEMBL7953326 | 0.75 | SIRT1 (0.61) | SIRT1SIRT3SIRT5SIRT2ADORA2B | |
| SCHEMBL7424268 | 0.75 | SIRT1 (0.50) | SIRT1SIRT3SIRT5SIRT2ADORA2B | |
| SCHEMBL13504596 | 0.75 | SIRT1 (0.40) | SIRT1SIRT3SIRT5SIRT2ADORA2B | |
| SCHEMBL28991327 | 0.74 | ALDH1A1 (0.72) | ALDH1A1CYP1A2CYP3A4TSHRMAPK1 | |
| SCHEMBL9903998 | 0.74 | SIRT1 (0.60) | SIRT1SIRT3SIRT5SIRT2ADORA2B | |
| SCHEMBL7468034 | 0.73 | SIRT1 (0.48) | SIRT1SIRT3SIRT5SIRT2ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034872-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2015-05-19 | — | — | US | disclosed |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-04-17 | — | — | US | disclosed |
| EP-2233472-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2014-01-15 | — | — | EP | disclosed |
| US-8614319-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-12-24 | — | — | US | disclosed |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2013-03-21 | — | — | US | disclosed |
| US-8349850-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-01-08 | — | — | US | disclosed |
| EP-2233472-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2010-09-29 | — | — | EP | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
| EP-2010505-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007110868-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | PDE5A, PDE3B, PDE3A | SIRT1 1260/4885SIRT3 1029/4885SIRT5 567/4885 |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | PDE5A, PDE3B, PDE3A | SIRT1 2031/4885SIRT3 1749/4885SIRT5 550/4885 |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | PDE5A, PDE3B, PDE3A | SIRT1 1260/4885SIRT3 1029/4885SIRT5 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.